Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

Hutrukin

Monoclonal antibody · Antagonist of IL-1α (IL1A) · developed by XBiotech

Phase 1 Most advanced trial (none active)

XBIT Developer

1 Registered trials

What is Hutrukin?

Hutrukin is a fully human IgG1 antibody that binds and blocks IL-1α biological activity. Generated from natural human immune response without in vitro modifications, it is designed to be non-immunogenic with pharmacokinetics similar to native immunoglobulin.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type: Monoclonal antibody
Targets: IL-1α (IL1A)
Mechanism: Antagonist of IL-1α (IL1A)
Developer: XBiotech, Inc. (XBIT)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 1

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT05098080	Phase 1	Pharmacokinetics	Completed	XBIT

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Pharmacokinetics

Other drugs acting on IL1A

Lutikizumab Phase 2 Natrunix Phase 2 Vilamakitug Phase 2

More from XBiotech

514G3 Phase 1/2 Natrunix Phase 2 Vilamakitug Phase 2

Sources

ClinicalTrials.gov NCT05098080

Updated Oct 3, 2026. Something wrong or missing? Report it on the XBIT page.

Follow XBIT, the company behind Hutrukin

See XBIT's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

XBIT catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z